A Study to Evaluate the Safety and Tolerability of Cendakimab in Chinese Healthy Participants

Launched by BRISTOL-MYERS SQUIBB · Nov 30, 2022

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants must be Chinese (both biological parents are ethnically Chinese).
• • Body mass index (BMI) of 18.0 through 28.0 kilograms/meter squared (kg/m\^2), inclusive. BMI = weight (kg)/\[height (m)\]\^2.
• • Body weight ≥ 50.0 kg.
• Exclusion Criteria:
• • History of clinically significant infection within 4 weeks of dosing on Day 1.
• • Significant medical history/condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study.
• • Condition(s) which may confound the ability to interpret data from the study, as determined by the investigator.
• • Other protocol-defined inclusion/exclusion criteria apply.

Trial Officials